We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Arthroscopic Knee Surgery and Sham Procedure Show Same Results

By HospiMedica International staff writers
Posted on 07 Jan 2014
Patients who underwent a placebo surgery experienced the same outcomes and incidence of symptoms as patients who actually underwent arthroscopic partial meniscectomy, according to a new study.

Researchers at the University of Helsinki (Finland) conducted a multicenter, randomized, sham-controlled trial in 146 patients (35–65 years of age) participating in the Finnish Degenerative Meniscal Lesion (FIDELITY) study who had symptoms consistent with a degenerative medial meniscus tear, and no knee osteoarthritis (OA). More...
Patients were randomly assigned to arthroscopic partial meniscectomy or to sham surgery. The primary outcomes were changes in the Lysholm score and the Western Ontario Meniscal Evaluation Tool (WOMET) score and in knee pain after exercise at 12 months after the procedure.

The results showed that there were no significant between-group differences in the change from baseline to 12 months in any primary outcome. The mean improvements in the Lysholm score for the partial-meniscectomy group was 21.7, compared with 23.3 points in the sham-surgery group; for the WOMET score, 24.6 and 27.1 points, respectively; and the score for knee pain after exercise was 3.1 and 3.3 points. There were no significant differences between groups in the number of patients who required subsequent knee surgery or serious adverse events. The study was published on December 26, 2013, in the New England Journal of Medicine (NEJM).

“By ceasing the procedures which have proven ineffective, we would avoid performing 10,000 useless surgeries every year in Finland alone,” said lead author Raine Sihvonen, MD. “The corresponding figure for the US is at least 500,000 surgeries.”

“Based on these results, we should question the current line of treatment according to which patients with knee pain attributed to a degenerative meniscus tear are treated with partial removal of the meniscus, as it seems clear that instead of surgery, the treatment of such patients should hinge on exercise and rehabilitation,” added senior author Teppo Järvinen, MD, PhD.

Arthroscopic meniscectomy is an outpatient minimally invasive surgical (MIS) procedure used to treat a torn meniscus cartilage in the knee, often resulting from a sport-related injury. Traumatic tears usually occur as a result of a twisting or hyperflexion injury, while degenerative tears are more common in people over 40 and may occur without a specific injury. Since only the outer 1/4 of the meniscus is vascularized, repairs are successful when the tear occurs in this region of the meniscus. Tears in the nonvascular region are unlikely to heal and therefore are removed.

Related Links:

University of Helsinki



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.